Cancer cachexia is regulated by selective targeting of skeletal muscle gene products

Swarnali Acharyya1, Katherine J Ladner, Lori L Nelsen

  • 1Division of Human Cancer Genetics, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus 43210, USA.

Insights

Cancer cachexia selectively targets myosin heavy chain, a key myofibrillar protein, through RNA-dependent mechanisms and the ubiquitin-proteasome pathway, not general muscle protein downregulation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Cachexia, a cancer-associated wasting syndrome, causes significant mortality.
  • The specific muscle gene products targeted by cachectic factors remain poorly understood.
  • It is unclear if muscle protein regulation during cachexia is general or selective.

Purpose of the Study:

  • To investigate the selectivity of cachectic factors in targeting muscle proteins.
  • To elucidate the mechanisms underlying myosin heavy chain reduction in muscle wasting.

Main Methods:

  • In vitro studies using myotubes.
  • In vivo studies using mouse models with colon-26 tumors.
  • Analysis of gene expression and protein degradation pathways.

Main Results:

  • Cachectic factors selectively reduced myosin heavy chain expression.
  • Tumor necrosis factor-alpha (TNF-alpha) plus interferon-gamma (IFN-gamma) reduced myosin via an RNA-dependent mechanism.
  • Myosin loss in tumor-bearing mice involved the ubiquitin-dependent proteasome pathway.

Conclusions:

  • Cancer cachexia involves selective targeting of specific myofibrillar proteins like myosin heavy chain.
  • Muscle wasting is not a generalized suppression of muscle gene products.
  • The mechanisms regulating protein expression during cachexia can be factor-specific.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...